211 related articles for article (PubMed ID: 34838186)
1. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.
Shapiro LC; Thakkar A; Campbell ST; Forest SK; Pradhan K; Gonzalez-Lugo JD; Quinn R; Bhagat TD; Choudhary GS; McCort M; Sica RA; Goldfinger M; Goel S; Anampa JD; Levitz D; Fromowitz A; Shah AP; Sklow C; Alfieri G; Racine A; Wolgast L; Greenberger L; Verma A; Halmos B
Cancer Cell; 2022 Jan; 40(1):3-5. PubMed ID: 34838186
[TBL] [Abstract][Full Text] [Related]
2. Seroconversion rates following COVID-19 vaccination among patients with cancer.
Thakkar A; Gonzalez-Lugo JD; Goradia N; Gali R; Shapiro LC; Pradhan K; Rahman S; Kim SY; Ko B; Sica RA; Kornblum N; Bachier-Rodriguez L; McCort M; Goel S; Perez-Soler R; Packer S; Sparano J; Gartrell B; Makower D; Goldstein YD; Wolgast L; Verma A; Halmos B
Cancer Cell; 2021 Aug; 39(8):1081-1090.e2. PubMed ID: 34133951
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
4. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S
J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774
[TBL] [Abstract][Full Text] [Related]
5. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.
Barrière J; Carles M; Audigier-Valette C; Re D; Adjtoutah Z; Seitz-Polski B; Gounant V; Descamps D; Zalcman G
Eur J Cancer; 2022 Feb; 162():182-193. PubMed ID: 35016032
[TBL] [Abstract][Full Text] [Related]
6. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.
Naranbhai V; St Denis KJ; Lam EC; Ofoman O; Garcia-Beltran WF; Mairena CB; Bhan AK; Gainor JF; Balazs AB; Iafrate AJ;
Cancer Cell; 2022 Jan; 40(1):103-108.e2. PubMed ID: 34990570
[TBL] [Abstract][Full Text] [Related]
7. Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer.
Samdaengpan C; Sungkasubun P; Chaiwiriyawong W; Supavavej A; Siripaibun J; Phanthunane C; Tantiyavarong W; Lamlertthon W; Ungtrakul T; Tawinprai K; Soonklang K; Thongchai T; Limpawittayakul P
JCO Glob Oncol; 2024 May; 10():e2300458. PubMed ID: 38781552
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
9. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity.
Delmonte OM; Bergerson JRE; Burbelo PD; Durkee-Shock JR; Dobbs K; Bosticardo M; Keller MD; McDermott DH; Rao VK; Dimitrova D; Quiros-Roldan E; Imberti L; Ferrè EMN; Schmitt M; Lafeer C; Pfister J; Shaw D; Draper D; Truong M; Ulrick J; DiMaggio T; Urban A; Holland SM; Lionakis MS; Cohen JI; Ricotta EE; Notarangelo LD; Freeman AF
J Allergy Clin Immunol; 2021 Nov; 148(5):1192-1197. PubMed ID: 34492260
[TBL] [Abstract][Full Text] [Related]
11. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
Ebinger JE; Fert-Bober J; Printsev I; Wu M; Sun N; Prostko JC; Frias EC; Stewart JL; Van Eyk JE; Braun JG; Cheng S; Sobhani K
Nat Med; 2021 Jun; 27(6):981-984. PubMed ID: 33795870
[TBL] [Abstract][Full Text] [Related]
12. Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.
Ludwig H; San-Miguel J; Munshi N; Sonneveld P; Mateos MV; Moreau P; Terpos E
Am J Hematol; 2021 Aug; 96(8):896-900. PubMed ID: 34057243
[No Abstract] [Full Text] [Related]
13. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
[TBL] [Abstract][Full Text] [Related]
14. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
15. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
16. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
Ghione P; Gu JJ; Attwood K; Torka P; Goel S; Sundaram S; Mavis C; Johnson M; Thomas R; McWhite K; Darrall A; DeMarco J; Kostrewa J; Mohr A; Rivas L; Neiders M; Suresh L; Segal BH; Griffiths EA; Ramsperger V; Shen L; Hernandez-Ilizaliturri FJ
Blood; 2021 Sep; 138(9):811-814. PubMed ID: 34189565
[No Abstract] [Full Text] [Related]
17. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Schmitt AM; Tippu Z; Farag S; Rogiers A; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Barber T; Emslie-Henry A; Caulfield-Lynch N; Byrne F; Shum B; Gerard CL; Deng D; Kjaer S; Song OR; Queval C; Kavanagh C; Wall EC; Carr EJ; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Shea RL; Gardner G; Murray D; Yousaf N; Jhanji S; Van As N; Young K; Furness AJS; Pickering L; Beale R; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Howell M; Nicholson E; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
Cancer Cell; 2022 Feb; 40(2):114-116. PubMed ID: 34968417
[No Abstract] [Full Text] [Related]
18. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer.
Zeng C; Evans JP; Chakravarthy K; Qu P; Reisinger S; Song NJ; Rubinstein MP; Shields PG; Li Z; Liu SL
Cancer Cell; 2022 Feb; 40(2):117-119. PubMed ID: 34986328
[No Abstract] [Full Text] [Related]
19. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
[TBL] [Abstract][Full Text] [Related]
20. A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS-CoV-2 mRNA vaccine.
Borgogna C; Ferrante D; Rosso G; Guglielmetti G; Lo Cigno I; Raviola S; Caneparo V; Quaglia M; Cantaluppi V; Gariglio M
J Med Virol; 2024 Jun; 96(6):e29710. PubMed ID: 38804187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
